Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer

被引:43
|
作者
Honselmann, Kim C. [1 ,2 ,3 ]
Pergolini, Ilaria [1 ,2 ]
Fernandez-del Castillo, Carlos [1 ,2 ]
Deshpande, Vikram [1 ,2 ]
Ting, David [2 ,4 ]
Taylor, Martin S. [1 ,2 ]
Bolm, Louisa [3 ]
Qadan, Motaz [1 ,2 ]
Wellner, Ulrich [3 ]
Sandini, Marta [1 ,2 ]
Bausch, Dirk [3 ]
Warshaw, Andrew L. [1 ,2 ]
Lillemoe, Keith D. [1 ,2 ]
Keck, Tobias [3 ]
Ferrone, Cristina R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Gastrointestinal Surg & Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Med Ctr Schleswig Holstein, Dept Surg, Campus Luebeck, Lubeck, Germany
[4] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
关键词
lymph node status; PDAC; recurrence; survival; SHORT-COURSE CHEMORADIATION; PROTON-BEAM THERAPY; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT TREATMENT; PANCREATICODUODENECTOMY; CAPECITABINE;
D O I
10.1097/SLA.0000000000003123
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. Summary Background Data: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues. Methods: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152). Results: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%,P< 0.001 and 64% vs. 78%,P= 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1P< 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1,P< 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1,P= 0.553), 24% with local disease (27% of pN0 and 23% of pN1,P= 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1,P= 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1,P= 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%,P= 0.435). Conclusion: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 50 条
  • [1] Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer
    Kim, Han Na
    Choi, Dong Wook
    Lee, Kyu Taek
    Lee, Jong Kyun
    Heo, Jin Seok
    Choi, Seong-Ho
    Paik, Seung Woon
    Rhee, Jong Chul
    Lowe, Anson W.
    PANCREAS, 2007, 34 (03) : 325 - 334
  • [2] Prognostic variables in node-negative and node-positive breast cancer
    Gasparini, G
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 321 - 331
  • [3] Prognostic variables in node-negative and node-positive breast cancer - editorial
    Giampietro Gasparini
    Breast Cancer Research and Treatment, 1998, 52 : 321 - 331
  • [4] Prognostic variables in node-negative and node-positive breast cancer - Introduction
    Giampietro Gasparini
    Breast Cancer Research and Treatment, 1998, 51 : 193 - 194
  • [5] Prognostic variables in node-negative and node-positive breast cancer - Introduction
    Gasparini, G
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (03) : 193 - 194
  • [6] Micrometastatic node-positive breast cancer: An analysis of outcomes in comparison to node-negative and macrometastatic node-positive disease
    Truong, P. T.
    Li, K.
    Lesperance, M.
    Chia, S.
    Macfarlane, R.
    Speers, C. H.
    Olivotto, A.
    CLINICAL ONCOLOGY, 2007, 19 (03) : S48 - S48
  • [7] Micrometastatic node-positive breast cancer: An analysis of outcomes in comparison to node-negative and macrometastatic node-positive disease
    Truong, P. T.
    Li, K.
    Lesperance, M.
    Chia, S.
    Macfarlane, R.
    Speers, C. H.
    Olivotto, I. A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S17 - S17
  • [8] Nm23 expression in node-positive and node-negative endometrial cancer
    Yalcinkaya, U.
    Ozuysal, S.
    Bilgin, T.
    Ercan, I.
    Saraydaroglu, O.
    Demir, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 (01) : 35 - 39
  • [9] Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer
    Murphy, Brittany L.
    Hoskin, Tanya L.
    , Courtney Day N.
    Habermann, Elizabeth B.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (09) : 2518 - 2525
  • [10] Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer
    Brittany L. Murphy
    Tanya L. Hoskin
    Courtney Day N. (Heins)
    Elizabeth B. Habermann
    Judy C. Boughey
    Annals of Surgical Oncology, 2017, 24 : 2518 - 2525